Zealand Pharma announced it will present Phase 2 clinical trial data for petrelintide, a long-acting amylin analog for obesity treatment, at the American Diabetes Association's 2026 Scientific Sessions in June. The ZUPREME-1 trial showed efficacy and safety results, highlighting Zealand's progress in developing innovative metabolic health therapies. This presentation is part of Zealand's collaboration with Roche and underscores their commitment to advancing obesity treatments. The data presentation includes multiple sessions and posters, signaling potential impact on future obesity management.
Mission Produce has finalized its acquisition of Calavo Growers, creating a stronger, vertically integrated fresh produce company with an expanded footprint in North America. This merger combines two leading avocado providers, enhancing sourcing, pac...
The US Surface Transportation Board (STB) has suspended its review of the proposed merger between Union Pacific (UP) and Norfolk Southern (NS), requiring the companies to provide additional detailed information. The STB and Canadian National Railway ...
Meta Platforms announced a quarterly cash dividend of $0.525 per share for its Class A and Class B common stock. The dividend will be paid on June 25, 2026, to shareholders recorded as of June 15, 2026. This move reflects Meta's ongoing commitment to...
Virgin Galactic's stock surged after a U.S. federal court granted preliminary approval for a settlement resolving two long-running shareholder derivative lawsuits. The settlement involves a $2.75 million payment from the company's insurers, with Virg...
At its 2026 Annual General Meeting, Alamos Gold shareholders voted with 78.39% turnout to re-elect all nominated directors and reappoint KPMG LLP as auditor. The meeting also saw approval of the company's executive compensation approach through a non...
